RecruitingNCT06086132
Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry
Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry (ISACS CARDIONCO-PREDICT)
Sponsor
University of Bologna
Enrollment
10,000 participants
Start Date
May 1, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Age 18 years old or older
- Capable of giving informed consent
- Diagnosis of cancer scheduled for treatment according to treating physician's discretion
- Life expectancy >1 year
- For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs
Exclusion Criteria4
- Age <18 years old
- Not able to give informed consent
- Life expectancy <1 year
- Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
COMBINATION_PRODUCTProspective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy
Follow-up visits at baseline, 3-months, and 1-year
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06086132